The Biochemistry Department of the International Centre for Neuroscience and Genomic Medicine carries out, in addition to its healthcare work, an important scientific activity. Since its creation in 1992, it has carried out its own R&D&I projects and has participated in various externally funded national and international research projects, as well as taking part in clinical trials for major pharmaceutical companies.
Its current scientific work focuses mainly on the following fields:
Biomarker study in Alzheimer's disease and other dementias
Study of biochemical biomarkers in the early diagnosis, monitoring and prognosis of age-related diseases such as Alzheimer's disease and other dementias.
Recent studies have focused on the assessment of the β-amyloid protein, oxidative stress, and vascular risk in dementias and their association with the genetics involved in these pathologies.
Development of risk bio-panels and early detection of prevalent diseases
Design of exclusive biochemical profiles for clinical use for risk detection, early diagnosis, and monitoring of prevalent diseases such as metabolic syndrome, osteoporosis, oxidative stress, cardiovascular risk, and diseases related to alterations in neurotransmitters, among others.
The use of biomarkers related to different etiopathogenic lines of the same pathology offers us a broader vision of the status of the disease. The inclusion of risk factors that favour the development, and that in most cases are modifiable, allows us to minimise or delay the evolution of these diseases.
In collaboration with other R&D&I departments of the Euroespes Group, the Biochemistry and Clinical Analysis laboratory works on the development of nutraceuticals with beneficial health properties.
From a biochemical point of view, different sensitive and specific biomarkers are selected and analysed in the evaluation of the biological properties of each of the nutraceuticals under development.